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Abstract: Muscarinic receptors have long been the target receptors for treatment of patients with 
overactive bladder (OAB). These patients experience symptoms of urgency, urinary frequency and 
nocturia, with or without urge incontinence (the involuntary leakage of urine associated with urge). 
Fesoterodine, a pro-drug, structurally and functionally related to tolterodine, is the newest agent 
developed for the treatment of OAB. Fesoterodine is broken down to the active metabolite, 5-hydroxy-
methyl-tolterodine (5-HMT) by non-specific esterases. This metabolism results in the complete 
breakdown of the parent compound and is responsible for dose related improvements in clinical efficacy 
and health related quality of life. Like other antimuscarinic agents including tolterodine, fesoterodine is 
associated with improvements in clinical variables related both to bladder filling (decreasing micturition 
frequency and increasing mean voided volume) and urgency (urgency and urge incontinence episodes). 
Improvements in health related quality of life following treatment with fesoterodine is indicated by 
improvements in 7 of the 9 variables measured by the King’s Health Questionnaire. Also like other 
antimuscarinic agents, fesoterodine use is associated with adverse events including dry mouth. However 
the incidence of dry mouth is reduced with fesoterodine, compared to oxybutynin, due to the improved 
bladder selectivity of 5-HMT. 
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Abstract: Muscarinic receptors have long been the target receptors for treatment of patients with 
overactive bladder (OAB). These patients experience symptoms of urgency, urinary frequency 
and nocturia, with or without urge incontinence (the involuntary leakage of urine associated 
with urge). Fesoterodine, a pro-drug, structurally and functionally related to tolterodine, is the 
newest agent developed for the treatment of OAB. Fesoterodine is broken down to the active 
metabolite, 5-hydroxy-methyl-tolterodine (5-HMT) by non-specific esterases. This metabolism 
results in the complete breakdown of the parent compound and is responsible for dose related 
improvements in clinical efficacy and health related quality of life. Like other antimuscarinic 
agents including tolterodine, fesoterodine is associated with improvements in clinical variables 
related both to bladder filling (decreasing micturition frequency and increasing mean voided 
volume) and urgency (urgency and urge incontinence episodes). Improvements in health related 
quality of life following treatment with fesoterodine is indicated by improvements in 7 of the 
9 variables measured by the King’s Health Questionnaire. Also like other antimuscarinic agents, 
fesoterodine use is associated with adverse events including dry mouth. However the incidence 
of dry mouth is reduced with fesoterodine, compared to oxybutynin, due to the improved blad-
der selectivity of 5-HMT.
Keywords: fesoterodine, 5-hydroxymethyl-tolterodine, muscarinic, overactive bladder, urgency, 
incontinence
Overview of the overactive bladder
Overactive bladder (OAB) is a debilitating chronic disorder experienced by 
approximately 17% of both men and women over the age of 40 years, with the 
prevalence increasing with increasing age.1,2 Patients with OAB typically experience 
symptoms of urgency, usually with frequency and nocturia, with or without urge 
incontinence (the involuntary leakage of urine associated with urge).3 Results from 
the National Overactive Bladder Evaluation (NOBEL) Programme conducted in the 
US indicated that OAB was more prevalent than other chronic conditions such as heart 
disease, sinusitis, and asthma.2
OAB is a chronic disease with a major negative influence on quality of life, 
especially associated with the limitations it places on physical and emotional roles, 
vitality and social functioning.4 The symptoms of OAB affect all aspects of life includ-
ing: social (limiting outings due to frequent need to urinate), psychological (loss of 
self esteem associated with incontinence), physical (limitations of physical activities 
due to fear of incontinence) and occupational (decreased productivity).3 OAB can 
also be associated with economic costs including; the personal costs of managing 
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incontinence, the treatment costs associated with managing 
symptoms and providing care for incontinent nursing home 
residents and costs associated with decreased work produc-
tivity. In the US, the economic costs associated with OAB 
in the year 2000, were estimated to be between US$12.02 
billion and US$17.5 billion.5 This makes the economic impact 
of OAB, comparable to the economic impact of influenza, 
arthritis and osteoarthritis.5
The cornerstone symptom of OAB is urgency1,6 which is 
defined as the complaint of a sudden compelling desire to pass 
urine which is difficult to defer.3 This symptom is associated 
with frequency of urination and nocturia. Approximately 66% 
of patients with OAB do not have urge incontinence and are 
classified as OAB dry.2 The remaining 33% of patients with 
OAB have urgency associated with incontinence and are 
classified as OAB wet.2 Urodynamic testing demonstrates 
that patients with OAB wet have detrusor overactivity, where 
urine leakage arises from involuntary detrusor contraction.3 
The etiology of these involuntary detrusor contractions 
remains uncertain.
There are numerous treatment options available for 
patients with OAB including biofeedback, electrical stimu-
lation, bladder training and pharmacotherapy, either alone 
or in combination. However, the primary treatment for the 
OAB is pharmacotherapy with muscarinic receptor antago-
nists7–9 which have been used for many years. Oxybutynin 
(Ditropan®) was the first muscarinic receptor antagonist to 
be introduced to OAB therapy. Newer antimuscarinic agents 
include the M
3
 selective antagonists, darifenacin (Enablex®) 
and solifenacin (VESIcare) and the relatively non-subtype 
selective antagonists, tolterodine (Detrol®) and its related 
compound fesoterodine (Toviaz®), which has only been 
recently introduced.
The role of muscarinic receptors 
in bladder physiology
The traditional dogma behind the treatment of OAB with 
muscarinic receptor antagonists was based on our understand-
ing of the nerves controlling the physiological functions of the 
bladder. During filling the bladder detrusor muscle expands 
at low pressure. During this time the stretch of the bladder 
wall initiates the release of mediators (such as ATP) from the 
urothelium that signals bladder fullness via the underlying 
afferent nerves.10 Signals from these afferent nerves are pro-
cessed in the Pontine micturition centre in the brain and, at an 
appropriate time, efferent parasympathetic nerves are activated. 
The efferent parasympathetic nerves release acetylcholine 
onto muscarinic receptors located on the detrusor muscle.11





) that have been cloned and pharmacologically 
characterized.12 In the urinary bladder, as in other smooth 
muscles, multiple muscarinic receptor subtypes have been 
identified.13 Binding and immunoprecipitation studies,14–17 
have demonstrated that the majority of muscarinic recep-
tors present in human detrusor muscle, are M
2
 receptor 
(∼70%) with smaller populations of M
3
 (20%) and M
1
 
(10%) receptors.17 Activation of muscarinic receptors by 
acetylcholine leads to contraction of the detrusor muscle and 
subsequent emptying of the bladder. Functional studies car-
ried out in M
3
 knockout mice18 and human detrusor strips19,20 
have demonstrated that muscarinic M
3
 receptors are the 
receptor subtype responsible for contraction of the detrusor 
muscle. Nevertheless, there is some evidence that M
2
 recep-
tors also have some functional importance.21,22 Traditionally 
the muscarinic antagonists used to treat OAB were thought 
to inhibit activation of the muscarinic receptors responsible 





receptor subtypes are associated with detrusor contraction, 
muscarinic receptor antagonists, have been characterized 
according to their affinity for these receptor subtypes.
Antimuscarinic therapy for OAB
OAB therapy began when oxybutynin was shown to reduce 
contractions of the rabbit detrusor in response to the musca-
rinic agonist carbachol23 although oxybutynin is not selective 
for any individual muscarinic receptor subtype (Table 1). 
Oxybutynin was then shown to be clinically effective at 
preventing detrusor spasms following transurethral surgery24 
which provided the impetus for antimuscarinic therapy for 
OAB. This was soon followed in the early 1980s with reports 
of oxybutynin providing symptomatic relief for patients with 
detrusor instability.25,26
In 1998 tolterodine, another muscarinic receptor 
antagonist was first introduced. Like oxybutynin, toltero-
Table  Range of Ki values (in nM) reported for antimuscarinic agents 
in cell lines expressing human muscarinic receptor subtypes
Compound M M M3 M4 M5
Oxybutynina 4.5 36.5 3.3 5.2 19.6
Tolterodineb 6.9 6.7 6.4 6.8 5.9
Fesoterodinec 11.9 5.1 26.9 8.9 4.5
5-HMTd 5.9 5.6 5.7 5.8 6.1
aData summarized from36,85–89 
bData summarized from27,87–92 
cData summarized from36,92 
dData summarized from27,36
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dine, is relatively non-selective for individual muscarinic 




 receptors of 6.4 
nM and 6.7 nM respectively).27 And also like oxybutynin, 
tolterodine is efficacious in the treatment of OAB.28–32 
However, the clinical efficacy of tolterodine has been 
demonstrated to be associated both with tolterodine itself, 
and with the generation of an active metabolite, 5-hydroxy-
methyl-tolterodine (5-HMT).33–35 Like tolterodine, 5-HMT 
demonstrates similar affinity for the individual muscarinic 




 receptors of 
5.7 nM and 5.6 nM respectively).27,36 The newest mus-
carinic antagonist for therapy of OAB is fesoterodine. 
Fesoterodine, which is structurally related to tolterodine, 
also results in the formation of the same active metabolite, 
5-HMT37,38 although the mechanism underlying production 
of 5-HMT are vastly different.
Pharmacokinetics of fesoterodine 
and tolterodine
The active metabolite of tolterodine, 5-HMT, is formed by 
cytochrome P450 2D6 (CYP2D6)34 (Figure 1) which is sub-
ject to polymorphism.39 The polymorphism of CYP2D6 is 
highly clinical relevant as it is responsible for variability in 
metabolism of more than 100 different drugs.40 Based on their 
CYP2D6 phenotype patients are characterized as extensive 
metabolizers, if they have two functional CYP2D6 alleles, or 
poor metbaolizers who lack functional CYP2D6 alleles.40 Up 
to 10% of white populations and 19% of black populations are 
characterized as poor metabolizers.40 In patients classified as 
extensive metabolizers, 81% of the absorbed tolterodine, is 
extracted during first pass metabolism through the liver,39 and 
hydrolyzed to 5-HMT with an average maximal plasma con-
centration of tolterodine and 5-HMT being similar (5.2 and 4.8 
ng/mL respectively).39 In contrast, in poor metabolizers only 
18% of tolterodine is extracted during first pass metabolism 
through the liver39 and the average maximal plasma concentra-
tion of tolterodine of is increased to 38 ng/mL while 5-HMT 
is not detectable.39 Furthermore the concentration of 5-HMT 
released from metabolism of tolterodine is highly variable 
(1 to 100 ng/mL)41 and this variability in the generation of 
the active metabolite makes individual tailoring of tolterodine 
dose necessary in some patients.39
Fesoterodine has been developed as a sustained release 
preparation with maximal plasma concentrations of 5-HMT 
detected approximately 4 to 6 hours after oral administration.42 
In contrast to tolterodine, the formation of the active metabo-
lite from fesoterodine is not dependent on CYP2D6 activity 
(Figure 1) but rather occurs due to hydrolysis of fesoterodine 
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by non-specific esterases. No fesoterodine is detected in the 
plasma of patients indicating that metabolism of fesoterodine 
is rapid and complete.41,43 Also, in contrast to tolterodine, there 
is little inter-subject variability in the generation of 5-HMT 
from fesoterodine, as the activity of the non-specific esterases 
is similar in all people.37,44 Oral administration of a single dose 
of 4 mg fesoterodine, results in a maximal plasma concentra-
tion of 5-HMT between 1 and 10 ng/mL,41,45 with plasma 
concentrations of 5-HMT overlapping in patients characterized 
as extensive (0.9 to 5.6 ng/mL) or poor metabolizers (2.0 to 
10.9 ng/mL).41 In addition, plasma concentrations of 5-HMT 
increases linearly with increasing fesoterodine dose.41 A large 
proportion of the active metabolite, 5-HMT, is transported in the 
plasma unbound (36 to 54%),39,42 in contrast to tolterodine which 
is almost entirely bound to serum albumin (3.7% unbound).39
Breakdown of 5-HMT, generated from either tolterodine 
or fesoterodine, to inactive metabolites occurs via cyto-
chrome P450 3A4 and CYP2D6 (Figure 1) and is therefore 
varied in extensive and poor metabolizers.45,46 Approximately 
70% of the fesoterodine dose is eliminated via the urine with 
approximately 16% being eliminated as 5-HMT42 the rest 
as inactive metabolites.43 The urine elimination of 5-HMT 
increasing proportionally with fesoterodine dose.43 Excre-
tion of 5-HMT is slowed in patients with renal impairment, 
however this delay in excretion was not associated with a 
significant increase in adverse events in these patients.42
Efficacy of fesoterodine 
and tolterodine in clinical trials
Both fesoterodine and tolterodine have been associated with 
clinical efficacy that exceeds placebo in a number of important 
clinical variables. Four recent randomized controlled trials 
have compared the clinical efficacy of fesoterodine with 
placebo,37,47–49 two of which also compared fesoterodine 
with tolterodine.47,49 Selected results from these clinical trials 
are summarized in Table 2. These results indicate that both 
fesoterodine and tolterodine have clinical efficacy against 
symptoms related to bladder filling (micturition frequency 
and mean voided volume) and urgency (urgency episodes, 
urge incontinence episodes).
In regards to symptoms related to bladder filling, treat-
ment for 12 weeks with a once daily dose of fesoterodine 
(4 mg) resulted in a significant decrease in micturition 
frequency (5.5% greater than the average placebo effect) 
which corresponds to 1.7 less micturitions per 24 hours. 
Fesoterodine (4 mg) was also associated with an increase 
in mean voided volume of 25.1 mL compared to an average 
increase in placebo of 9.3 mL. These changes in clinical out-
comes with 4 mg fesoterodine were comparable to tolterodine 
(4 mg) (Table 2).47,49
Fesoterodine was also effective against symptoms related 
to urgency. Treatment with 4 mg fesoterodine resulted in 
a significant decrease in urge incontinence episodes and 
urgency episodes. In OAB wet patients the decrease in urge 
incontinence episodes was 26.6% greater than the average 
placebo effect; that is 1.9 less episodes of urge incontinence 
per 24 hours (Table 2). In addition there was a significant 
decrease in urgency episodes which was 8.2% greater than 
the average placebo effect (Table 2). This corresponds to 
2 less urgency episodes per 24 hours.37,47–49
One interesting feature of fesoterodine treatment is 
that the improvements in clinical efficacy are shown to be 
Table  Efficacy of fesoterodine and tolterodine in 12 week clinical trials for OAB therapy
Range of 
baseline values
Placeboa,b Fesoterodinea Tolterodine ERb
4 mg 8 mg 4 mg
Micturition frequency 11.5–12.9 −9.3% −15.5%*,† −16.9%*,† −15.6%*
MVV (mL) 150–160 +9.04 +23.0*,† +33.2*,†,** +25.1*
Urgency episodes 11–12.5 −7.5% −16.9%*,† −18.8%*,† −17.5%*
UUI episodes 3.7–4.0 −40.7% −67.5%*,† −77.9%*,†,** −56.3%
Continent days/week 0.6–0.8 +1.7 +2.6*,† +3.0*,†,** +2.6*
Notes: Statistical significance reported: *P  0.05 vs placebo, †P  0.001 vs placebo and **P  0.05 vs 4 mg fesoterodine treatment.
Definition of measures:
Micturition frequency is the number of times a patient passed urine (including incontinence episodes) in a 24-hour period.
MVV is the mean voided volume (mL) per micturition determined from a 1-day collection period.
Urgency episodes is the number of times a patient recorded an urgency episode with or without incontinence per day determined from a 3-day bladder diary.
Urge urinary incontinence is the number of times the patient experiences involuntary leakage of urine accompanied by or immediately preceded by urgency in a 24-hour 
period determined from a 3-day bladder diary.
Continent days per week were normalized from a 3-day bladder diary.
aData summarized from37,47–49
bData summarized from47,49
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increased with increasing dose (8 mg compared to 4 mg) 
(Table 2). Treatment with 8 mg fesoterodine resulted in a 
significantly greater decrease in urge incontinence episodes 
per 24 hours (9.1% greater than the average decrease with 
4 mg fesoterodine), together with an increase in mean voided 
volume (8 mL greater than the average improvement with 
4 mg fesoterodine). In addition, treatment with 8 mg fesotero-
dine was also associated with an increase in the number of 
continent days per week to 3.1 days compared to 2.7 days 
with fesoterodine 4 mg.47–49
Fesoterodine is unusual in showing this dose response 
relationship as a similar relationship has not been dem-
onstrated for other antimuscarinic agents including 
tolterodine,50–52 or the muscarinic M
3
 receptors selective 
agents, darifenacin53 and solifenacin.54 It is likely that 
this dose response relationship is a result of the simple 
metabolism of fesoterodine by the non-specific esterases 
and the associated linear relationship between fesoterodine 
dose and plasma concentrations of the active compound, 
5-HMT.41,43
In addition to the improvements in clinical outcomes 
fesoterodine has also been associated with improvements 
in Health Related Quality of life (HRQoL). The King’s 
Health Questionnaire, which examines 9 domains related 
to quality of life,55 has been used to assess improvements in 
HRQoL in people who suffer from OAB following 12 week 
treatment with fesoterodine.56,57 Significant improvement in 
five or more domains of the King’s Health Questionnaire is 
considered to indicate meaningful improvement in patient 
quality of life.58 Similar to clinical efficacy, improvements 
in HRQoL were related to fesoterodine dose. Treatment 
with 8 mg fesoterodine showed significant improvements 
(compared with placebo) in 8 of the 9 domains assessed by 
the King’s Health Questionnaire. While 4 mg fesoterodine 
(and tolterodine 4 mg), showed significant improvements 
(compared with placebo) in 7 of the 9 domains.59 The 
domains where fesoterodine was associated with improve-
ment include: severity/coping, emotions, role limitations, 
physical limitations, social limitations, sleep/energy, per-
sonal relationship and incontinence impact.56,57 Of these 
improvements all except benefit for personal relationship 
were seen in patients who were classified as both OAB 
wet and OAB dry.56 Treatment with 8 mg fesoterodine 
also showed significantly greater improvement compared 
to 4 mg fesoterodine in domains of severity/coping and 
emotions.57
Adverse events associated with 
fesoterodine and tolterodine
While muscarinic antagonists can be used to effectively 
treat OAB in approximately 65% of patients, numerous 
patients discontinue therapy long term due to adverse events 
including dry mouth and constipation.59 These adverse events 
occur due to a lack of organ selectivity of antimuscarinic 
agents60 as muscarinic receptors are not only located on the 
detrusor muscle but also in the salivary glands61 and smooth 
muscle of the gastrointestinal tract.13,62 The incidence of these 
adverse events in clinical trials of fesoterodine and tolterodine 
are summarized in Table 3.37,47–49
Dry mouth was the most common adverse event 
associated with fesoterodine use (Table 3), although most 
patients described it as mild to moderate. Twenty percent of 
patients being treated with 4 mg fesoterodine reported dry 
mouth.37,47–49,63 This was increased to 35% in patients being 
treated with 8 mg fesoterodine37,47–49 compared to an incidence 
of 6% in placebo (Table 3). Although common, dry mouth 
did not account for a large number of patients withdrawing 
from the 12 week clinical trials (Table 3). The incidence of 
dry mouth with fesoterodine (4 mg) was comparable to the 
incidence in patients treated with tolterodine (4 mg)30,47,49,64 
however it was considerably lower than that reported with 
oxybutynin (Table 3).30,65
The reason for the decrease in incidence of dry mouth 
with fesoterodine (and tolterodine) compared to oxybutynin 
may lie in the selectivity of 5-HMT for the bladder over the 
salivary gland (Table 4). Radiologand binding studies in 
Table 3 Incidence of dry mouth and constipation in patients treated with oxybutynin, tolterodine, and fesoterodine
Antimuscarinic dose Dry mouth Constipation Discontinuation due 
to adverse events
Reference
Oxybutynin 5 and 10 mg 32.9% 7.3% 1.8% Data summarized from30,65
Tolterodine ER 4 mg 19.8% 4% 2.5% Data summarized from30,47,49,64
Fesoterodine 4 mg 20.2% 4.4% 5% Data summarized from37,47–49,63
Fesoterodine 8 mg 34.7% 5.1% 6.8% Data summarized from37,47–49
Placebo 4.9% 2.5% 3.1% Data summarized from37,47–49,65
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salivary gland and bladder have demonstrated that oxybu-
tynin has a three times higher affinity for salivary gland over 
the bladder (Table 4). In contrast tolterodine and 5-HMT 
have an affinity for the bladder that is twice that for the 
salivary gland (Table 4). Further to this, functional studies 
have examined the selectivity of oxybutynin, tolterodine and 
5-HMT, for the bladder and salivary gland by comparing the 
concentrations required to inhibit detrusor contractions and 
salivation in vivo. Similar to the results from radioligand 
binding studies, oxybutynin inhibits salivation at a concentra-
tion that is approximately one-third lower than that required 
to inhibit bladder contraction (Table 4) indicating some 
degree of selectivity for the salivary gland.66 In contrast, 
5-HMT inhibits bladder contractions at a lower concentra-
tion than that required to inhibit salivation27 indicating some 
degree of selectivity for the bladder. The reasons for this 
bladder selectivity of 5-HMT is unknown and cannot be 
explained simply by selectivity for individual muscarinic 
receptor subtypes.
Antimuscarinic agents show clinical 
efficacy against the symptom of 
urgency
Fesoterodine and tolterodine have demonstrated efficacy 
against symptoms of urgency as demonstrated by improve-
ments in the clinical variables of urge incontinence episodes 
and urgency episodes per 24 hours (Table 2).37,47–49,67 This is 
similar to reports from clinical trials with other muscarinic 
receptor antagonists, including the M
3
 selective agent 
solifenacin68–70 and trospium.71 However, these beneficial 
effects, on the symptoms of urgency, raises the question as to 
how urgency is sensed, what receptors are involved and why 
antimuscarinic agents are effective against urgency. Answer-
ing these questions and understanding how these antimus-
carinic agents are efficacious against urgency is important, 
as urgency is the cornerstone symptom for OAB and the 
symptom that patients identify as their most bothersome.6 
Recent reviews have suggested that at therapeutic doses, 
muscarinic antagonists do not appear to inhibit bladder 
contractility,8,72 and their activity is now thought to be during 
bladder filling to increase bladder capacity and to decrease 
urgency8 actions not attributable to inhibition of muscarinic 
receptors located on the detrusor.
Radioligand binding studies in both pig73 and human 
bladder17 have demonstrated M
2
 (70%) and M
3
 (30%) mus-
carinic receptors in the bladder mucosa. Mucosal muscarinic 
receptors have also been demonstrated using molecular 









.17,74,75 Immunohistochemical studies 
have localized muscarinic receptor immunoreactivity to 
the bladder urothelium74–76 and to suburothelial myofibro-
blasts.76,77 The role of these mucosal muscarinic receptors 
in bladder micturition remains unclear. However, they may 
represent a site of action for the muscarinic receptor antago-
nists used to treat OAB.
Recent, in vivo studies in rat bladder have demonstrated 
that intravesical administration of carbachol can induce 
detrusor overactivity,78 where as intravesical instillation of 
muscarinic antagonists including oxybutynin,79 tolterodine80 
and darifenacin81 reduces stretch activated afferent nerve 
firing in rat bladder, an effect also seen following systemic 
administration of oxybutynin.82 Furthermore, clinical efficacy 
has been associated, in patients with OAB, with intravesical 
instillation of oxybutynin83,84 It is possible that following oral 
administration of fesoterodine or tolterodine the presence 
of the active metabolites, 5-HMT, in the urine as a result of 
urinary excretion is partly responsible for the clinical efficacy 
of these agents.
Conclusion
Fesoterodine is a pro-drug developed to produce the active 
metabolite, 5-hydroxy-methyl-tolterodine (5-HMT) via the 
actions of non-specific esterases. This metabolism of fes-
oterodine results in the complete breakdown of the parent 
Table 4 Selectivity of antimuscarinic agents for bladder and salivary gland as determined by radioligand binding and in vivo functional studies
Compound Radioligand binding studies In vivo functional studies
Ki (nM) ID50 (nmol/kg iv)
a
Bladder Salivary gland Bladder Salivary gland Reference
Oxybutynin 9.8 3.02 215 76 Data summarized from66,86,93
Tolterodine 2.7 4.8 101 257 Data summarized from66,90,91
5-HMT 2.9 5.2 15 40 Data summarized from27
Note: data are not available for fesoterodine as it is completely metabolized to 5-HMT.
aID50 determined from in vivo functional studies where antagonists were infused into anesthetized animals. Bladder contraction was stimulated by intra-arterial acetylcholine. 
Salivation was stimulated by electrical stimulation of the chorda-lingual nerve.27,66,91
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compound and is responsible for dose related improve-
ments in clinical efficacy and health related quality of life. 
Fesoterodine, like tolterodine and other antimuscarinic 
agents, has been shown to have clinical efficacy for the 
treatment of patients suffering from OAB. Treatment with 
fesoterodine is associated with improvements in clinical vari-
ables related both to bladder filling (decreasing micturition 
frequency and increasing mean voided volume) and urgency 
(urgency and urge incontinence episodes). Fesoterodine 
is also associated with significant improvements in health 
related quality of life as indicated by improvements in at 
least 7 of the 9 variables measured by the King’s Health 
Questionnaire. Fesoterodine, like other antimuscarinic 
agents, is associated with adverse events such as dry mouth 
and constipation. However the incidence of these adverse 
events is reduced compared, to the original muscarinic 
antagonist oxybutynin, due to the improved bladder selectiv-
ity of 5-HMT.
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